Board of Directors
Zhihong Xu, Ph.D., Honorary Chairman
Dr. Zhihong Xu, an internationally recognized leader in science and education, has been a member of Boyalife’s Board of Directors since 2009. He served as past president of Peking University from 1999 through 2008 as well as vice president of the Chinese Academy of Sciences from 1992 to 2001. Dr. Xu is currently chairman of the Chinese National Committee of UNESCO’s Man and the Biosphere (MAB) program. He also serves as an academician at the Chinese Academy of Sciences, professor of life sciences at Peking University, director of the Chinese Plant Physiology Society, professor emeritus at the University of Hong Kong, and vice president of the China Society of Biological Engineering. Dr. Xu has been presented with numerous honorary degrees, including an honorary doctor of science degree by De Montfort University (1994) and Nottingham University (2000) in the UK, Hong Kong City University (2001), Wasada University in Japan (2002), and McGill University in Canada (2003), an honorary doctor of law degree by Melbourne University in Australia (2003); and an honorary doctorate by the University of Montreal (2004) in Canada. In 1994, he was also named as an honorary professor at Hong Kong University.
Chris Xu, Ph.D., Chairman
Chris Xu, Ph.D., is the current president and chairman of Boyalife Group, which he founded in 2009. Prior to founding Boyalife, Dr. Xu served as a project leader at Pfizer, as a director of research at two publicly-traded biopharmaceutical companies and as a vice president at Founder Group, a Chinese technology conglomerate focused on information technology, pharmaceuticals, real estate, finance, and commodities trading. Dr. Xu’s expertise spans several diverse therapeutic areas, including arthritis & inflammation, cardiovascular disease, autoimmunity, oncology and diabetes. He has authored over forty publications and has been recognized by numerous professional societies for his contributions to biomedical research. Dr. Xu received his Ph.D. in immunology from Washington University School of Medicine (St. Louis, USA) and an executive MBA from Emory University (Atlanta, USA).
Lisa Li, M.Sc., MBA
Lisa Li is co-founder, president and chief executive officer of BoyaLife Group. Prior to joining the company, Ms. Li held managerial positions of increasing responsibility at PepsiCo, General Mills, and SSA Global Technologies. Ms. Li received a Bachelor’s degree from Chinese Agriculture University (Beijing), a Master’s in Applied Statistics from North Dakota State University (Fargo) and an MBA from the Peking University School of Business (Beijing). Ms. Li also serves on BoyaLife’s board of directors.
Chunming Guo, Ph.D., MBA
Dr. Guo currently serves as Senior Vice President and Chief Financial Officer of the Boyalife Group, and Head of the Boyalife Genomics Group. He brings to the Boyalife team extensive experience in corporate finance and management. Prior to joining Boyalife, Dr. Guo served as General Manager and Board Director for various companies with Wanhua Chemicals Group, one of the largest chemical corporations in China (SH:600309). Dr. Guo received a Ph.D. from Nanjing Institute of Technology and an executive MBA from Peking University (Beijing). Dr. Guo also serves as Board Director for Meihua Group Co. Ltd. (SH:600873).
Ruiping Xiao, MD, Ph.D.
Prior to joining Boyalife as Chief Scientific Officer, Head of Boyalife Institute of Translational Medicine, Dr. Xiao served as the laboratory director of the Receptor Signaling Section at National Institute of Health from 1996 through 2006. Since 2006, she has served as the founding director of the Institute of Molecular Medicine at Peking University. Dr. Xiao served on a wide range of academic committees and editorial boards, including New England Journal of Medicine. Dr. Xiao obtained her MD from Tongji Medical University (China) and her Ph.D. from the University of Maryland School of Medicine.